MENLO THERAPEUTICS INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Menlo Therapeutics Inc. (MNLO) for potential violation of federal securities laws
Shareholders are urged to contact Wolf Haldenstein Adler Freeman & Herz LLP
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating potential claims on behalf of purchasers of Menlo Therapeutics Inc. ("Menlo" or the "Company") (MNLO). Shareholders who purchased Menlo stock in or after the Company's January 2018 initial public offering ("IPO") and have incurred losses are encouraged contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.
The investigation focuses on whether Menlo and certain of its officers and/or directors have violated federal securities laws, and specifically focuses on the Company's filings with the U.S. Securities and Exchange Commission (SEC) in connection with the IPO regarding its second Phase 2 clinical trial of patients treated with serlopitant.
On April 9, 2018, Menlo revealed that Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis failed to meet its primary or key secondary efficacy endpoints. The Company also said that the trial did not show a significant difference between patients treated with serlopitant and patients treated with placebo.
Following this news, Menlo stock dropped 76.8% to close at $8.17 on April 9, 2018.
Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.
Follow the firm and learn about newly filed cases on Twitter and Facebook.
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
SOURCE: Wolf Haldenstein Adler Freeman & Herz LLP
